



**St. Jude Children's  
Research Hospital**

Finding cures. Saving children.

ALSAC • DANNY THOMAS, FOUNDER



2022

ALSAC/ST. JUDE  
ANNUAL REPORT



The mission of St. Jude Children’s Research Hospital® is to advance cures, and means of prevention, for pediatric catastrophic diseases through research and treatment. Consistent with the vision of our founder, Danny Thomas, no child is denied treatment based on race, religion or a family’s ability to pay.

ALSAC – American Lebanese Syrian Associated Charities – is the fundraising and awareness organization for St. Jude. ALSAC is dedicated solely to raising the funds and awareness to operate and maintain St. Jude, now and in the future.



After several years of chemotherapy at a pediatric hospital near her home, a relapse would lead doctors to refer Luna to St. Jude where her treatment consisted of bone marrow transplants, chemotherapy, and immunotherapy. “For us, St. Jude has been a blessing,” said Luna’s father. Scan the QR code to learn more.

This page: St. Jude patient **Luna**, blood cancer, pictured with her dad

Cover: St. Jude patient **Pepe**, cancerous tumor, pictured with his mom





# CHILDHOOD LEUKEMIA SURVIVOR

prepares to pursue a medical career, wants to give back

**J**uan Sebastián stood before his computer during a video conference call to the United States and enthusiastically showed his black school jacket given to final-year students at his high school in Colombia. The year 2022 is stitched in one arm.

Months before he graduated high school in July, the 18-year-old was preparing for graduation and the start of college. He was looking forward to the final months of high school when he would go to Cancun with his classmates for a final school trip. A few days before his graduation ceremony, he attended a formal dinner celebration with his parents and close friend to commemorate the big milestone.

The activities are a culmination of years of long hours of studying, but also a reminder of all the hurdles Juan Sebastián has overcome. The teenager battled leukemia for years as a child, forcing him to miss school. When he had a relapse, he was treated in the U.S. at St. Jude Children's Research Hospital and missed nearly a year of school as well as birthday parties, soccer games and a school trip to Canada.

"It's quite incredible to think there was a point in my life when I didn't know if I was going to get to graduate," he said. "Now a new stage of my life begins. There are so many stories, so many times when I couldn't go to school, so many moments that I could not go to class because I was in the

hospital. But now I'm moving forward, that's all behind me. And that's something very beautiful and special."

Juan Sebastián, who ranks third in his graduating class, has been accepted to the Universidad de los Andes in Bogotá, where he will study medicine. His dream is to become a doctor and one day work at St. Jude.







“St. Jude is hope, it’s light and everything to me,” he said. “They saved my life. I don’t know how to explain what St. Jude means to me, but it’s just hope to be alive and to continue to grow.”

Juan Sebastián was 10 years old when he was diagnosed with acute lymphoblastic leukemia, the most common type of childhood cancer. He received grueling chemotherapy in Bogotá, which often left him weak and tired. At times, his parents didn’t think he was well enough to go to school, but a dedicated student, Juan Sebastián did not like to be absent.

On some tough days, his father, Luis, recalled, his son would mix water with baking soda and lemon juice in a container that he would carry with him in school to help him through headaches and bouts of nausea.

Juan Sebastián was in remission for a few weeks before an analysis on his bone marrow showed that his leukemia had returned. Doctors in Colombia began a new round of treatment, but his prognosis was poor, his parents said. While Juan Sebastián organized a fundraising concert to help other children with cancer, friends urged his family to look elsewhere and to seek help at St. Jude because of its work with childhood

cancers. Eventually, he was referred to the research hospital and traveled to Memphis.

When they arrived, it was cold and gloomy, Juan Sebastián recalled. But as soon as they entered the hospital with its bright lights and colorful wall art, they felt a sense of ease and hope that he would get better.

“They welcome you with a smile,” he recalled. “My dad told us that here at St. Jude they were going to save his son’s life.”

He received a bone marrow transplant as well as chemotherapy and radiation therapy. The relapse, though, didn’t stop him from learning. Juan Sebastian attended the St. Jude Imagine Academy by Chili’s to stay on track with his studies during treatment. He also continued his piano lessons in Memphis, an activity which he started earlier to help reduce the neuropathy in his hands caused by earlier chemotherapy. When he returned to South America, he studied extra hours to fill in learning gaps and remain in the same grade as his friends.

“Despite all the difficulties of his illness, he managed to get excellent grades,” Luis said. “He is very excited about his academic achievements, but the biggest emotion for us is to have him with us.”

A few months ago, Juan Sebastián and his mother, Maria Clara, went to a tattoo artist and got matching tattoos on their left arms. The tattoos are of the



St. Jude logo. Juan Sebastián said the tattoo is his constant reminder to not get too hung up on little things.

“There are times in life when one forgets a bit of what happened and everything they suffered and the really hard moments they lived through, and one begins to worry about things that are not worth it,” he said. “It’s also a reminder of that goal that I want to reach of trying to help and give other people opportunity, like St. Jude gave me the opportunity of life.”

**“They saved my life. I don’t know how to explain what St. Jude means to me, but it’s just hope to be alive and to continue to grow.”**

– Juan Sebastián



# research HIGHLIGHTS

## Pushing T cells down “memory lane” may improve cancer therapy

Scientists at St. Jude identified a molecular mechanism that in a preclinical study unlocked the promise of CAR T-cell therapy for the treatment of solid tumors.

June 2022 | *Nature*

## Research reveals surprising inactivation mechanism for a voltage-gated ion channel

Scientists at St. Jude are studying voltage-gated ion channels (VGICs). Their work revealed a previously unknown mechanism of inactivation for one such channel that plays an important role in how neurons and muscles respond to electric signals sent by the nervous system.

May 2022 | *Molecular Cell*

## Study finds jumping junk DNA is a novel cause of childhood brain cancer

Scientists have found a novel cause of aggressive pediatric brain cancer. The St. Jude study is the first to document how a transposon, a piece of DNA that “jumps” around the genome, can donate its promoter to drive the expression of an oncogene.

April 2022 | *Acta Neuropathologica*

## CAR T cells target AML, spare bone marrow

Scientists at St. Jude have developed the first GRP78 targeted chimeric antigen receptor (CAR) T cell. Their GRP78 CAR T cell successfully targeted and destroyed acute myelogenous leukemia (AML) cells in the lab.

January 2022 | *Nature Communications*

## Immune responses support COVID-19 vaccination regardless of when people were infected

Scientists at St. Jude have evaluated how vaccination against, and infection with, SARS-CoV-2 affects the immune system. The results confirm that immunity by infection is not better than vaccination because both mount similar T-cell responses. In individuals who have already experienced COVID-19, getting vaccinated still expands T-cell memory and immune activation.

April 2022 | *Nature Immunology*

## Phase separation underlies leukemia caused by NUP98 fusion oncoproteins

Scientists at St. Jude have a new understanding of how a group of well-known fusion oncoproteins causes leukemia. The findings show the importance of liquid-liquid phase separation (LLPS), a process cells use to organize proteins and other molecules. LLPS is a key part of the mechanism driven by NUP98 fusion oncoproteins that transforms blood stem cells into leukemia.

December 2021 | *Cancer Discovery*

## Cell-free DNA identifies early signs of relapse in pediatric medulloblastoma

Scientists at St. Jude have shown that cell-free DNA from cerebrospinal fluid (CSF) can be used to detect measurable residual disease (MRD) in children treated for the brain tumor medulloblastoma. The researchers developed a test to detect MRD, and thus the risk of relapse, earlier than a recurrent tumor would be identified using a traditional imaging scan.

October 2021 | *Cancer Cell*

## The PANoptosome: a new frontier in innate immune responses

St. Jude immunologists have identified how immune sensors in infected cells organize and launch a multi-faceted innate immune response to infections with live viruses and bacteria.

September 2021 | *Nature*

## Comprehensive clinical sequencing opens door to the promise of precision medicine

St. Jude investigators have demonstrated that comprehensive genomic sequencing of all pediatric cancer patients is feasible and essential to capitalize on the lifesaving potential of precision medicine.

July 2021 | *Cancer Discovery*

## Discovery shows how tuning the immune system may enhance vaccines and ease disease

Immunologists at St. Jude have identified a biological pathway that selectively controls how key immune cells, called T follicular helper cells, mature into functional components of the immune system.

July 2021 | *Nature*

Art featured here and on pages 10-11 inspired by St. Jude patient **Kaleb**.

St. Jude patient **Kaleb**, blood disorder







## At St. Jude, a collaborative approach takes scientific research **FROM BENCH TO BEDSIDE**

On the campus of St. Jude Children's Research Hospital in Memphis, where buildings with labs stand alongside buildings with clinics, Giles Robinson, M.D., shares samples of tumor cells from his patients with Paul Northcott, Ph.D., who leads a lab that studies how those tumor cells behave at a molecular level and how patients respond to different therapies.

What Northcott finds about the differences within medulloblastoma helps inform how doctors like Robinson treat their patients. Their close collaboration has spawned new, more effective treatments for medulloblastoma, the most common malignant brain tumor in children.

It's an example of what's known at St. Jude as the "bench-to-bedside" model: how discoveries at a lab bench translate to better care for patients in beds.

Over the last decade, Northcott and Robinson have identified 13 subgroups of medulloblastoma, some that require less radiation and chemotherapy, while others more. Until these recent discoveries, doctors treating medulloblastoma had thought it was one disease requiring uniform treatment for the more than 400 children diagnosed with it each year in the United States.

"It turned a light on for me," Robinson said. "On one hand it's overwhelming, and on the other hand it's fantastic because we can come up with multiple different treatments that suit these categories of medulloblastoma."

Robinson and Northcott shared their discoveries and the benefits of collaboration at the St. Jude Partner Summit event, which hosted representatives of corporations that support St. Jude. The partners had a chance to listen to the doctors and also tour labs to learn more about the research that happens at the hospital.

Visitors explored parts of the recently constructed Inspiration4 Advanced Research Center, a 625,000-square-foot facility that features state-of-the-art equipment and technology in laboratories for the research of Developmental Neurobiology, Immunology and Cellular and Molecular Biology.

Scientists showed visitors how small dishes that fit in the palms of hands contained tumor cells for various cancers to be studied for their features, strengths and vulnerabilities to devise treatment and cures.

In one dish, cells of a cancer that affects the muscles and soft tissue, called "rhabdomyosarcoma," float like harmless specks of dust. When allowed to flourish over a week in conditions similar to the human muscle, images from the microscope show the cells grow, no longer spheres but a dense mesh spreading and filling the plate. The solid tumor lab is focused on learning how these cancers grow and spread and what it takes to stop them.

*"Having first-hand visibility into the labs was eye-opening to understand the amount of time, technology and resources needed to detect and understand the impact of one genetic cell in a billion that can impact a child's life."*

— Carmen Murillo  
Senior Director of Marketing  
for Melting Pot Restaurants

The lab also tracks elusive cancer cells that survive treatment in some patients. These rogue cells, few in number, remain hidden sometimes for years but then unexpectedly mount a resurgence causing difficult-to-treat relapses. St. Jude scientists are working with doctors to improve survival rates for recurrent cases — rates that have been largely stagnant for more than two decades.

"Having first-hand visibility into the labs was eye-opening to understand the amount of time, technology and resources needed to detect and understand the impact of one genetic cell in a billion that can impact a child's life," said Carmen Murillo, Senior Director of Marketing for Melting Pot Restaurants, which has raised over \$13.9 million for St. Jude since its partnership began in 2003. "As tedious as the research may be, it is the most important, groundbreaking work."

The work in his brain tumor lab is "very challenging," Northcott admitted, and the answers he and his fellow scientists seek lead to more dead ends than discoveries.

"It's a 90 percent failure rate, maybe 95 percent," Northcott said. "But I'm driven by the fascination and curiosity and possibility for discovery. That's what gets me up in the morning."

Jill Maness, Manager, Community Relations for AutoZone, which has raised more than \$51 million since its partnership with St. Jude began in 2006, called the work the doctors, researchers and entire staff do every day at St. Jude "nothing short of remarkable."

"I can't imagine the gambit of emotional strain parents face upon learning that their child has been diagnosed with cancer or any life-threatening disease," Maness said. "St. Jude does everything possible to make sure that children have the most successful outcomes and that families are comforted and alleviated of as much stress as possible."



Spurred by the mission and inspired by a trailblazer,

# MISSISSIPPI DOCTOR GIVES TO SUPPORT ST. JUDE

**F**or the longest time, Dr. Vernon Rayford didn't understand his father's love of running. But then in his 30s, when his body reminded him it needed new ways to get strong, he laced up his sneakers and began jogging some of the same routes his father had: past quiet neighborhoods with neat brick homes, prayerful Methodist churches and kudzu draped North Mississippi hills.

Running brought him closer to his father. And then one day in December 2016, as they ran the St. Jude Memphis Half Marathon together, running unexpectedly brought him cause and purpose, too.

"It's my favorite part of the race, going through campus," Rayford said. "Seeing the patients there, knowing who you're [running] for, it just really spoke to me."

Over the last six years, Rayford has run marathons in New York, Chicago and across the country in support of St. Jude.

As he learned more about St. Jude – how it had opened as an inclusive hospital in 1962 at the height of civil rights strife in the South and welcomed children regardless of race, and how it employed and promoted doctors, scientists and staff of color, as well – Rayford knew this was a cause that deserved his support.

Rayford's support for St. Jude grew even more as he began to feel kinship with a renowned African American physician who helped St. Jude become a leader in care and research for sickle cell disease. This year, Rayford made a \$10,000 commitment toward the campaign honoring the late Dr. Rudolph Jackson, one of the first Black doctors at St. Jude.

Rayford learned that in the 1960s, Dr. Jackson's care for patients with conditions such as rampant anemia, parasitic infections and growth impairments led him to help develop a program under which St. Jude

*Hearing about his dedication,  
persistence, innovation, and hearing  
how that led to 40 years of lives saved,  
improved quality of lives...it's inspiring.*

**Dr. Vernon Rayford**

enrolled thousands of local infants and mothers to receive nutritional assistance, medicine. Ultimately, that program served as a prototype for WIC, the federal initiative for women, infants and children.

Rayford himself has spent his years as a primary care physician in North Mississippi helping improve the health of families in rural, often marginalized communities of color.

"I wish I'd known him, because that would've been an incredible (lesson) of the challenges of being the first, of being someone who started work when things were about as bad as it could be in terms of civil rights," said Rayford.

Rayford said he's particularly moved by the pioneering work Jackson did in the treatment of sickle cell disease at St. Jude. Jackson ventured into low-income neighborhoods in Memphis to enhance the education and treatment of children and families affected by the debilitating, painful and often deadly disease. By the early 1970s, Jackson had built the program to such a stature that he was hired to lead the federal government's efforts to fight the disease. "Hearing about his dedication, persistence, innovation, and hearing how that led to 40 years of lives saved, improved quality of lives...of lives not measured by time between emergency room visits, time between crises, it's inspiring," Rayford said.





## FY22 ALSAC/St. Jude Boards of Directors and Governors

The members of the ALSAC/St. Jude Boards of Directors and Governors are volunteers who serve without compensation. They come from across the country to support the lifesaving work of St. Jude, and many represent the second and third generations of their families to serve on the Boards. An honorary body of emeritus members recognizes the distinguished service on the Boards by those unable to continue to actively participate.

### ALSAC Board of Directors

#### Officers

**J. David Karam II**  
CEO, Sbarro Inc.  
*Chair*

**Frederick M. Azar, M.D.**  
Chief of Staff, Campbell Clinic  
*Vice Chair*

**Martha Perine Beard**  
Retired  
*Secretary*

### St. Jude Board of Governors

#### Officers

**Paul J. Ayoub**  
Partner, Nutter McClennen & Fish LLP  
*Chair*

**Judy A. Habib**  
President and CEO,  
KHJ Brand Activation  
*Vice Chair*

**Frederick R. Harris Jr., M.D.**  
Gastroenterologist, GastroOne  
*Secretary*

#### Members

**Joyce A. Aboussie**  
Owner and CEO, Aboussie &  
Associates

**Joseph S. Ayoub Jr.**  
President, Varuna Strategies LLC

**Sheryl A. Bourisk**  
Partner, BoMin Creative Productions

**Robert A. Breit, M.D.**  
Chief of Radiology, Northwestern  
Lake Forest Hospital

**Terry L. Burman**  
Retired

**Ann M. Danner**  
Co-Founder, First Women's Bank  
of Chicago (in formation)

**Joseph M. DeVivo**  
CEO, InTouch Health

**Fred P. Gattas III, PharmD**  
Director of Medical & Safety Affairs,  
Curium

**Ruth C. Gaviria**  
Founder and Chief Brand Strategist,  
Kite String Branding

**Gabriel G. Haddad, M.D.**  
Physician-in-Chief,  
Rady Children's Hospital

**Charles C. Hajjar**  
Owner, Hajjar Management Co. Inc.

**Fouad M. Hajjar, M.D.**  
Pediatric Hematologist/Oncologist,  
Advent Health for Children

**Scott A. Kupor**  
Managing Partner, Andreessen Horowitz

**Sharon L. McCollam**  
Retired

**Michael D. McCoy**  
Chief of Police, Washington  
Police Department

**Robert T. Molinet**  
Retired

**Ramzi N. Nuwayhid**  
Private Wealth Advisor,  
Merrill Lynch Private Banking  
and Investment Group

**Thomas J. Penn III**  
President and Owner,  
Los Angeles Football Club

**Christina M. Rashid**  
Founder and Managing Member,  
Lotos Groupe LLC

**Camille F. Sarrouf Jr.**  
Associate Justice, Trial Court – Superior  
Court Department

**Joseph C. Shaker**  
President, Shaker Recruitment  
Marketing

**Joseph G. Shaker**  
Chairman of the Board,  
Shaker Recruitment Marketing

**George A. Simon II**  
Retired

**Michael C. Simon**  
Managing Principal,  
Traverse Pointe Partners

**Tony Thomas**  
Partner, Witt/Thomas Productions

**Richard M. Unes**  
Senior Project Manager,  
Peoria Metro Construction

**Paul H. Wein**  
Partner, LaFave Wein & Frament PLLC

**Susan R. Windham-Bannister**  
President and CEO, Biomedical  
Growth Strategies LLC

**Tama H. Zaydon**  
Executive Director of Investments,  
Oppenheimer & Co. Inc.

#### Emeritus Members (Non-voting members of the Boards)

**Thomas G. Abraham**  
Chairman of the Board,  
Anthony R. Abraham Foundation

**Susan Mack Aguillard, M.D.**  
Pediatrician, Pediatrics East

**Mahir R. Awdeh, M.D.**  
Cardiologist, Cardiology Associates  
of Memphis

**James B. Barkate**  
President, Southern Abstracts Inc.

**Jack A. Belz**  
Chairman and CEO,  
Belz Enterprises

**Stephen J. Camer, M.D.**  
General Surgeon,  
New England Baptist Hospital

**Leslie S. Dale**  
Retired

**George Elias Jr.**  
Attorney, Law Offices  
of George Elias, Jr.

**Hasan M. Elkhatib**  
Retired

**Fred P. Gattas Jr.**  
President, Gattas Company

**Christopher B. George, M.D.**  
Pediatric Hematologist/Oncologist,  
Florida Cancer Specialists

**Paul K. Hajar**  
Retired

**Sam F. Hamra**  
Chairman, Hamra Enterprises

**Frederick R. Harris**  
Retired

**Theodore Hazer**  
Retired

**Bruce B. Hopkins**  
Retired

**Richard J. Karam**  
Attorney, Law Offices  
of Richard J. Karam

**James A. Kinney**  
Retired

**Salli E. Le Van**  
Retired

**Donald G. Mack, M.D.**  
Retired

**Paul J. Marcus**  
President, Marcus Capital  
Management Inc.

**James O. Naifeh**  
Retired

**Talat M. Othman**  
President, Grove Financial Inc.

**Manal B. Saab**  
CEO, Sorensen Gross  
Construction Services

**Frederick W. Smith**  
Chairman, President and CEO,  
FedEx Corporation

**Ronald A. Terry**  
Retired

**Terre Thomas**  
Writer

**Pat Kerr Tigrett**  
President and CEO, Pat Kerr Inc.

**Thomas C. Wertz**  
Senior Vice President of Wealth  
Management, UBS Financial Services

**Robert P. Younes, M.D.**  
Medical Director, Montgomery  
County Department of Correction &  
Rehabilitation

**Ramzi T. Younis, M.D.**  
Physician, Bascom Palmer  
Eye Institute

### Ex Officio Voting Members

**James R. Downing, M.D.**  
President and CEO, St. Jude  
Children's Research Hospital

**Richard C. Shadyac Jr.**  
President and CEO, ALSAC

### Chief Governance Officer/ Corporate Secretary

Leah J. Domitrovic

### Manager – Board Programs

Misty D. Aucoin

### Executive Assistant

Anita A. Johnson

### Administrative Specialist

Kimberly A. Ballard

### Epsilon Sigma Alpha Representative

Robin Bussey  
(Non-elected member)

### National Committee Members:

Salem A. Abraham

John D. Farina

Jason Thomas Gordon

Emil D. Haddad

Edmond R. Haggard Jr.

Alice W. Handy

Dionne T. Kirschner

Albert J. Mansour

Alexander P. Miceli

Julie A. Richards

Scott A. Vogel

### St. Jude National Outreach Director

Marlo Thomas

*For the current list of officers and members of the ALSAC/St. Jude Boards of Directors and Governors, please visit [stjude.org](http://stjude.org).*



## St. Jude Executive Committee

**James R. Downing, M.D.**  
President and Chief Executive Officer

**Greg Armstrong, MD, MSCE**  
Member, Department of Epidemiology and Cancer Control

**Aseem Ansari, Ph.D.**  
Chair, Chemical Biology and Therapeutics

**M. Madan Babu, Ph.D., FRSC**  
Member, Structural Biology  
Director, Center of Excellence for Data Driven Discovery

**Justin Baker, M.D.**  
Chief, Division of Quality of Life and Palliative Care  
Director, Hematology/Oncology Fellowship Program

**Suzanne Baker, Ph.D.**  
Co-Leader, Neurobiology and Brain Tumor Program

**Shari Capers**  
Vice President, Strategic Planning and Decision Support

**John Crispino, Ph.D., MBA**  
Member, Hematology  
Director, Division of Experimental Hematology

**Andrew Davidoff, M.D.**  
Chair, Surgery

**Robyn Diaz, J.D.**  
Chief Legal Officer  
Senior Vice President

**Michael Dyer, Ph.D.**  
Chair, Developmental Neurobiology

**David Ellison, M.D., Ph.D.**  
Chair, Pathology

**Richard Finkel, M.D.**  
Director, Translational Neurology Division

**Elizabeth Fox, M.D., M.S.**  
Senior Vice President, Clinical Trials Research  
Associate Director for Clinical Research, Comprehensive Cancer Center

**Amar Gajjar, M.D.**  
Chair, Pediatric Medicine

**Terrence Geiger, M.D., Ph.D.**  
Deputy Director for Academic and Biomedical Operations  
Senior Vice President

**Stephen Gottschalk, M.D.**  
Chair, Bone Marrow Transplant and Cellular Therapy

**Doug Green, Ph.D.**  
Chair, Immunology Department

**Gerard Grosveld, Ph.D.**  
Chair, Genetics

**Melissa Hudson, M.D.**  
Director, Cancer Survivorship Division  
Co-Leader, Cancer Prevention and Control Program

**Babis Kalodimos, Ph.D.**  
Chair, Structural Biology

**Pat Keel**  
Chief Financial Officer  
Senior Vice President

**Richard Kriwacki, Ph.D.**  
Co-Leader, Cancer Biology Program

**Jon McCullers, M.D.**  
Senior Executive Associate Dean of Clinical Affairs, UTHSC

**Peter McKinnon, Ph.D.**  
Member, Vice Chair, Cell and Molecular Biology

**Thomas Merchant, DO, Ph.D.**  
Chair, Radiation Oncology

**Motomi Mori, Ph.D., MBA**  
Chair, Biostatistics

**Charles Mullighan, MBBS (Hons), MSc, M.D.**  
Member, Pathology  
Deputy Director, Comprehensive Cancer Center

**Robin Mutz, MPPM, BSN, RNC, NEA-BC**  
Senior Vice President  
Chief Nurse Executive

**Ellis Neufeld, M.D., Ph.D.**  
Clinical Director  
Executive Vice President

**Alberto Pappo, M.D.**  
Director, Solid Tumor Division  
Co-Leader, Developmental Biology and Solid Tumor Program

**Zoltan Patay, M.D., Ph.D.**  
Interim Chair, Diagnostic Imaging

**Keith Perry**  
Chief Information Officer  
Senior Vice President

**Sean Phipps, Ph.D.**  
Chair, Psychology

**Ching-Hon Pui, M.D.**  
Chair, Oncology Department  
Director, China Region, St. Jude Global

**Charles Roberts, M.D., Ph.D.**  
Cancer Center Director  
Executive Vice President

**Les Robison, Ph.D.**  
Chair, Epidemiology

**Carlos Rodriguez-Galindo, M.D.**  
Chair, Global Pediatric Medicine  
Executive Vice President

**P. David Rogers, PharmD, Ph.D., FCCP**  
Chair, Department of Pharmacy and Pharmaceutical Sciences

**Martine Roussel, Ph.D.**  
Member, Tumor Cell Biology

**Charles Sherr, M.D., Ph.D.**  
Chair, Tumor Cell Biology

**J. Paul Taylor, M.D., Ph.D.**  
Chair, Cell and Molecular Biology

**Elaine Tuomanen, M.D.**  
Chair, Infectious Diseases

**Mitch Weiss, M.D., Ph.D.**  
Chair, Hematology

**Stephen White, DPhil**  
Dean, St. Jude Graduate School of Biomedical Sciences

**Kelvin Womack**  
Vice President, Chief Diversity and Inclusion Officer

**Jinghui Zhang, Ph.D.**  
Chair, Computational Biology

**Virgil Holder – Ex Officio**  
Vice President  
Chief of Staff

## ALSAC Leadership Team

**Richard C. Shadyac, Jr.**  
President and Chief Executive Officer

**Ike Anand**  
Chief Operating Officer

**Emily Callahan**  
Chief Marketing Officer

**Steve Froehlich**  
Chief Revenue Officer and Chief Development Officer

**Kera Getter-Wright**  
Chief Financial Officer

**Annette F. Green**  
Chief People Officer

**Sara Hall**  
Chief Legal Officer

**Martin Hand**  
Chief Donor Officer

**Melanee Hannock**  
Chief Digital Officer

**David Jacques,**  
Senior Vice President,  
Chief Information Officer

**Anurag Pandit**  
Chief Investment Officer

**Coury Shadyac**  
Senior Vice President,  
Territories



St. Jude patient **Eliza**, eye cancer



fiscal year 2022 combined

# FINANCIAL HIGHLIGHTS

Years ended June 30 (in thousands)

**2022**    **2021**

**REVENUES**

Total Support	\$2,415,238	\$2,073,494
Net Patient Service Revenue (Insurance Recoveries)	118,236	127,721
Research Grants	153,205	133,767
Net Investment (Loss) Income	(387,566)	1,864,093
Other	32,519	16,002
<b>TOTAL REVENUES</b>	<b>\$2,331,632</b>	<b>\$4,215,077</b>

**EXPENSES**

**Program Expenses**

Patient Care Services	551,616	524,965
Research	585,569	520,687
Education, Training and Community Support	256,278	211,269

**TOTAL PROGRAM EXPENSES**

1,393,463    1,256,921

Fundraising	356,737	300,554
Administrative and General	278,792	247,657

**TOTAL EXPENSES**

\$2,028,992    \$1,805,132

**LOSS ON DISPOSAL OF PROPERTY AND EQUIPMENT**

(524)    (616)

Change in Net Assets	302,116	2,409,329
Beginning Net Assets	8,973,553	6,564,224

**ENDING NET ASSETS**

\$9,275,669    \$8,973,553



St. Jude patient Olivia, brain tumor





St. Jude patient **Rinoa**,  
brain cancer

To read more inspiring St. Jude stories,  
visit [stjude.org/inspire](https://stjude.org/inspire)

To view the 2022 St. Jude Annual Report  
online, visit [stjude.org/financials](https://stjude.org/financials)